Although the introduction of now well-established standard therapy protocols, involving surgical resection, radiation, and chemotherapy4 as well as guidance by MGMT promoter methylation status5, has substantially improved clinical outcomes, 5-year survival in patients with glioblastoma has been largely constant at only 6.9%1. The gene discussed is MGMT; the disease is glioblastoma.